Stay updated with breaking news from Negative Predictive Value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Clinical utility of 18F-fluciclovine being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization
Using best practice guidelines, they developed a mixed-effects deep learning model to classify images as healthy or COVID-19 accurately.
Arquer Diagnostics' ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA First patients recruited for bladder cancer recurrence monitoring study News provided by Share this article SUNDERLAND, England, July 27, 2021 /PRNewswire/ -- ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe. ADXBLADDER is now being evaluated in a bladder c...
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 3, 2021 /PRNewswire/ -- As the world has adapted to the initial phase of the global pandemic, and vaccines are being manufactured
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging Getty Images January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography...